ES2124883T3 - Compuestos antiviricos. - Google Patents

Compuestos antiviricos.

Info

Publication number
ES2124883T3
ES2124883T3 ES94912709T ES94912709T ES2124883T3 ES 2124883 T3 ES2124883 T3 ES 2124883T3 ES 94912709 T ES94912709 T ES 94912709T ES 94912709 T ES94912709 T ES 94912709T ES 2124883 T3 ES2124883 T3 ES 2124883T3
Authority
ES
Spain
Prior art keywords
pct
nucleoside analog
mono
sec
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94912709T
Other languages
English (en)
Inventor
Bernt Borretzen
Are Dalen
Finn Myhren
Kjell Torgeir Stokke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Norsk Hydro ASA
Original Assignee
Norsk Hydro ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norsk Hydro ASA filed Critical Norsk Hydro ASA
Application granted granted Critical
Publication of ES2124883T3 publication Critical patent/ES2124883T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/052—Imidazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Abstract

SE SUMINISTRAN NUEVOS COMPUESTOS QUE TIENEN PROPIEDADES ANTIVIRALES DE LA FORMULA B-S-O-FA, EN LA CUAL O ES OXIGENO, B-S ES UN ANALOGO DE NUCLEOSIDO EN DONDE B REPRESENTA UN SISTEMA DE ANILLO HETEROCICLICO OPCIONALMENTE SUSTITUIDO, S ES UN DERIVADO MONOSACARIDO, Y FA ES UN GRUPO DE ACIL O UN ACIDO GRASO C18 O C20 MONO-INSATURADO, DICHO ACIDO GRASO SE ESTERIFICA CON UN GRUPO DE HIDROXIL DE LA MOLECULA DE AZUCAR DEL ANALOGO DE NUCLEOSIDO O CON UN GRUPO DE HIDROXIL EN EL GRUPO NO CICLICO DEL ANALOGO NUCLEOSICO.
ES94912709T 1993-04-05 1994-04-05 Compuestos antiviricos. Expired - Lifetime ES2124883T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939307043A GB9307043D0 (en) 1993-04-05 1993-04-05 Chemical compounds

Publications (1)

Publication Number Publication Date
ES2124883T3 true ES2124883T3 (es) 1999-02-16

Family

ID=10733340

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94912709T Expired - Lifetime ES2124883T3 (es) 1993-04-05 1994-04-05 Compuestos antiviricos.

Country Status (21)

Country Link
US (1) US6153594A (es)
EP (1) EP0693077B1 (es)
JP (1) JP3049258B2 (es)
KR (1) KR100309194B1 (es)
AT (1) ATE171457T1 (es)
AU (1) AU685104B2 (es)
CA (1) CA2158853C (es)
CZ (1) CZ287755B6 (es)
DE (1) DE69413529T2 (es)
DK (1) DK0693077T3 (es)
ES (1) ES2124883T3 (es)
FI (1) FI111370B (es)
GB (1) GB9307043D0 (es)
HK (1) HK1003437A1 (es)
HU (1) HU228064B1 (es)
NZ (1) NZ263888A (es)
PL (1) PL177263B1 (es)
RU (1) RU2139884C1 (es)
SK (1) SK281231B6 (es)
UA (1) UA41361C2 (es)
WO (1) WO1994022887A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9515279D0 (en) * 1995-07-25 1995-09-20 Norsk Hydro As Improved therapeutic agents
US6703394B2 (en) 1996-02-16 2004-03-09 Medivir Ab Acyclic nucleoside derivatives
US5869493A (en) * 1996-02-16 1999-02-09 Medivir Ab Acyclic nucleoside derivatives
EP0986570B9 (en) * 1997-01-24 2004-01-02 ConPharma AS Gemcitabine derivatives
US5891881A (en) * 1997-11-21 1999-04-06 Clarion Pharmaceuticals Inc. Aminoheterocycle-substituted glycerols
AU1412299A (en) * 1997-11-25 1999-06-15 Protarga, Inc. Nucleoside analog compositions and uses thereof
HUP0103711A3 (en) 1998-07-09 2003-11-28 Sankyo Company Ltd Chuo Ku Novel antimicrobial compounds
DE69922529T2 (de) * 1998-10-16 2005-12-15 Schering Corp. Ribavirin-interferon-alpha-kombinationstherapie zur vernichtung nachweisbarer hcv-rna in chronisch hepatitis c infizierten patienten
US6277830B1 (en) 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
TWI245047B (en) 1999-08-20 2005-12-11 Sankyo Co Novel A-500359 derivatives
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
EP1282632A1 (en) 2000-04-20 2003-02-12 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1736478B1 (en) * 2000-05-26 2015-07-22 IDENIX Pharmaceuticals, Inc. Methods and compositions for treating flaviviruses and pestiviruses
AU2003222197A1 (en) * 2002-01-16 2003-09-02 The Regents Of The University Of California Inhibition of rna function
AP2005003213A0 (en) 2002-06-28 2005-03-31 Univ Cagliari 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections.
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CN101172993A (zh) 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
US20040077607A1 (en) * 2002-10-21 2004-04-22 Uckun Fatih M. Aryl phosphate derivatives of d4T with potent anti-viral activity against hemorrhagic fever viruses
WO2004039995A1 (en) * 2002-11-01 2004-05-13 Evogenix Pty Ltd Mutagenesis methods using ribavirin and/or rna replicases
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
CA2509687C (en) 2002-12-12 2012-08-14 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
WO2004084453A2 (en) * 2003-03-20 2004-09-30 Microbiologica Quimica E Farmaceutica Ltd. METHODS OF MANUFACTURE OF 2'-DEOXY-β-L-NUCLEOSIDES
EP1680435A1 (en) * 2003-11-03 2006-07-19 Cognis IP Management GmbH Acyl ribonucleosides and acyl deoxyribonucleosides
FR2874016B1 (fr) * 2004-06-30 2006-11-24 Centre Nat Rech Scient Cnrse Nanoparticules de derives de la gemcitabine
US8114847B2 (en) 2005-03-16 2012-02-14 Case Western Reserve University Selective inhibitors of translesion DNA replication
WO2008147454A1 (en) * 2006-11-16 2008-12-04 Case Western Reserve University Selective inhibitors of translesion dna replication
NO324263B1 (no) * 2005-12-08 2007-09-17 Clavis Pharma Asa Kjemiske forbindelser, anvendelse derav ved behandling av kreft, samt farmasoytiske preparater som omfatter slike forbindelser
CA2634749C (en) 2005-12-23 2014-08-19 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
US8497292B2 (en) 2005-12-28 2013-07-30 Translational Therapeutics, Inc. Translational dysfunction based therapeutics
UA99308C2 (ru) * 2007-09-26 2012-08-10 Маунт Синай Скул Оф Медсин Аналог азацитидина и его применение
WO2013033705A2 (en) 2011-09-01 2013-03-07 Case Western Reserve University Non-natural nucleosides as theranostic agents
US9821173B2 (en) 2013-02-08 2017-11-21 Case Western Reserve University Anti-cancer agents and methods of use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1325798A (en) * 1970-09-24 1973-08-08 Upjohn Co Derivatives of 2,2-anhydro-ara-cytidine
US3920630A (en) * 1970-09-24 1975-11-18 Upjohn Co 2,2{40 -Anhydro-ara-cytidine compounds and process of preparation
US3984396A (en) * 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
US3998807A (en) * 1972-03-03 1976-12-21 Syntex (U.S.A.) Inc. Arabinofuranosyl cytosines and methods of making
GB1482736A (en) * 1974-03-18 1977-08-10 Icn Pharmaceuticals 1-(beta-d-ribofuranosyl)-1,2,4-triazole acid derivatives
US3960836A (en) * 1974-07-22 1976-06-01 Eli Lilly And Company Acylated derivatives of pyrazofurin and process for their preparation
JPS5159880A (en) * 1974-11-22 1976-05-25 Asahi Chemical Ind N44 ashirunukureoshidojikarubonsanesuteruno seiho
DE3100478A1 (de) * 1981-01-09 1982-08-12 Dr. Thilo & Co GmbH, 8021 Sauerlach 5'ester von pyrimidinnucleosiden mit antiviraler wirksamkeit, verfahren zur herstellung und daraus hergestellte arzneimittel
US4531001A (en) * 1982-03-23 1985-07-23 Brigham Young University 2-β-D-ribofuranosylselenazole-4-carboxamide compounds
US4684631A (en) * 1984-10-09 1987-08-04 Toyama Chemical Co., Ltd. Novel 5-fluoro-2-deoxyuridine derivatives and salts thereof, process for producing the same, and antitumor agents containing the same
JPH0655755B2 (ja) * 1985-01-23 1994-07-27 富山化学工業株式会社 新規な５−フルオロ−２′−デオキシウリジン−３′−ホスフエ−ト誘導体およびその塩
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
JPS6483092A (en) * 1987-09-24 1989-03-28 Arakawa Chotaro & Co Novel n6,n6-dimethyladenosine derivative having carcinostatic activity, its production and carcinostatic agent containing said derivative as active component
JPH0278696A (ja) * 1988-09-13 1990-03-19 Shoichiro Ozaki ５−フルオロウラシル誘導体
US5216142A (en) * 1989-04-17 1993-06-01 Efamol Holdings Plc Anti-virals
GB2260319B (en) * 1991-10-07 1995-12-06 Norsk Hydro As Acyl derivatives of nucleosides and nucleoside analogues having anti-viral activity
US5405837A (en) * 1993-05-18 1995-04-11 Indiana University Foundation Method for the treatment of neoplastic disease utilizing tiazofurin and ribavirin

Also Published As

Publication number Publication date
JP3049258B2 (ja) 2000-06-05
US6153594A (en) 2000-11-28
HU9502896D0 (en) 1995-11-28
CZ259395A3 (en) 1996-06-12
FI111370B (fi) 2003-07-15
CZ287755B6 (en) 2001-01-17
DK0693077T3 (da) 1999-06-14
EP0693077B1 (en) 1998-09-23
HUT73659A (en) 1996-09-30
SK281231B6 (sk) 2001-01-18
DE69413529D1 (de) 1998-10-29
CA2158853A1 (en) 1994-10-13
UA41361C2 (uk) 2001-09-17
DE69413529T2 (de) 1999-04-29
CA2158853C (en) 1999-07-27
AU6514194A (en) 1994-10-24
KR100309194B1 (ko) 2002-06-20
SK123395A3 (en) 1996-04-03
HU228064B1 (en) 2012-09-28
FI954727A (fi) 1995-10-04
WO1994022887A1 (en) 1994-10-13
NZ263888A (en) 1998-05-27
FI954727A0 (fi) 1995-10-04
HK1003437A1 (en) 1998-10-30
JPH08508477A (ja) 1996-09-10
ATE171457T1 (de) 1998-10-15
RU2139884C1 (ru) 1999-10-20
AU685104B2 (en) 1998-01-15
PL310970A1 (en) 1996-01-22
PL177263B1 (pl) 1999-10-29
EP0693077A1 (en) 1996-01-24
GB9307043D0 (en) 1993-05-26

Similar Documents

Publication Publication Date Title
ES2124883T3 (es) Compuestos antiviricos.
YU89792A (sh) O-heteroaril, o-alkilheteroaril, o-alkenil-heteroaril i o-alkinilheteroaril makrolidi, o-h
ES2115665T3 (es) Derivado de triterpeno.
ES2183023T3 (es) Composicion farmaceutica estabilizada con un agente basico.
DE59706982D1 (de) Thermoplastisch verarbeitbare stärke bzw. stärkederivat-polymermischungen
ATE16488T1 (de) M-4- und isom-4-derivate, ihre herstellung und diese enthaltende zusammensetzungen.
AR246527A1 (es) Procedimiento para la preparacion de n-acil-n,n'-di-lisogangliosidos, n'-acil-n,n'-di-lisogangliosidos y n,n'-diacil-n,n'-di-lisogangliosidos.
ES2078055T3 (es) Prostaglandinas.
MY114765A (en) Preparation for epidermis
EP0536402A4 (en) Piperidine derivative
IE782359L (en) Phenylgylcine derivatives
TW347333B (en) Antiviral pharmaceutical and veterinary compositions
ES2117976T3 (es) Preparacion de derivados n-acetil neuraminicos.
GB2380939B (en) Treatment or prevention of auto-immune diseases
KR0140401B1 (en) Anti-bloom triglyceride compositions
ES8609366A1 (es) Un procedimiento para preparar un derivado de ester de des- glucoteicoplanina
AU2426592A (en) New ganglioside derivatives
ES8609482A1 (es) Un metodo para producir acido dihidrodesoxigriseolico y sa- les y esteres del mismo
ATE92498T1 (de) Primycinkomponenten und verfahren zur trennung des antibiotischen komplexes.
KR890008134A (ko) 브라씨노스테로이드 유도체 및 식물 성장 조절제
DK508885A (da) Esterderivat af antibiotekum l 17046 og fremgangsmaade til fremstilling deraf
ES2111791T3 (es) Esteres de acidos grasos de derivados de metilglucosido.
BR9707342A (pt) Dihidrobensofurano e compostos correlatod úteis como agentes antiinflamatórios
GR75173B (es)
DE69120670D1 (de) Lipo-oligosaccharide als pflanzenspezifisches regulierendes mittel, verfahren zu ihrer herstellung und ihre verwendungen

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 693077

Country of ref document: ES